Idorsia | Portfolio overview

Compound	Mechanism of action	Target indication	Status	More Information

QUVIVIQ™ (daridorexant)	Dual orexin receptor antagonist	Insomnia	Commercially available in the US, Germany, Italy, Switzerland, Spain, the UK, Canada, Austria, France, and Sweden; approved throughout the EU	Investor webcast
TRYVIO™ (aprocitentan)	Dual endothelin receptor antagonist	Systemic hypertension in combination with other antihypertensive drugs	Commercially available in the US	Investor webcast
JERAYGO™ (aprocitentan)	Dual endothelin receptor antagonist	Resistant hypertension in combination with other antihypertensive drugs	Approved in the EU; Marketing authorization applications submitted in the UK, Canada, and Switzerland	Investor webcast
Lucerastat	Glucosylceramide synthase inhibitor	Fabry disease	Phase 3 primary endpoint not met, open-label extension study ongoing Phase 3 focused on renal function in preparation
ACT-1004-1239	ACKR3/CXCR7 antagonist	Demyelinating diseases including multiple sclerosis	Phase 2 in preparation
ACT-777991	CXCR3 antagonist	Vitiligo	Phase 2 in preparation
Sinbaglustat	GBA2/GCS inhibitor	Rare lysosomal storage disorders	Phase 1 complete
IDOR-1117-2520	Undisclosed	Immune-mediated disorders	Phase 1 ongoing
IDOR-1134-2831	Synthetic glycan vaccine	Clostridium difficile infection	Phase 1 ongoing

Compound	Mechanism of action	Target indication	Partner: Terms	Status
QUVIVIQ™ (daridorexant)	Dual orexin receptor antagonist	Insomnia	Simcere: license to develop and commercialize for the Greater China region	Approved for the treatment of insomnia in Hong-Kong
QUVIVIQ™ (daridorexant)	Dual orexin receptor antagonist	Insomnia	Nxera Pharma: license to develop and commercialize for Asia-Pacific region (excluding China)	Approved for the treatment of insomnia in Japan
Daridorexant	Dual orexin receptor antagonist	Insomnia	Simcere: license to develop and commercialize for the Greater China region	NDA submitted in Greater China
Selatogrel	P2Y₁₂ inhibitor	Suspected acute myocardial infarction	Viatris: worldwide development and commercialization rights	Phase 3 “SOS-AMI” program ongoing
Cenerimod	S1P₁ receptor modulator	Systemic lupus erythematosus	Viatris: worldwide development and commercialization rights (excluding Japan, South Korea, and certain countries in the Asia-Pacific region)	Phase 3 “OPUS” program ongoing
Daridorexant	Dual orexin receptor antagonist	Posttraumatic stress disorder (PTSD)	US Department of Defense (DOD): Idorsia supports a clinical study sponsored by the US DOD to develop new therapies to treat PTSD	Phase 2
ACT-1002-4391	EP₂ / EP₄ receptor antagonist	Immuno-oncology	Owkin: global license to develop and commercialize	Phase 1 in preparation

Bench to bedside